Progress towards personalized therapeutics: Biologic- and risk-directed therapy for neuroblastoma

Expert Review of Neurotherapeutics

Volumn 11, Issue 10, 2011, Pages 1411-1423

  Gustafson, William Clay ^a,b   Matthay, Katherine K ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ALK; INRG; MIBG; MYCN; neuroblastoma; risk stratification

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ALISERTIB; ALKYLATING AGENT; ANAPLASTIC LYMPHOMA KINASE; ANTHRACYCLINE; BEVACIZUMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FENRETINIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; ISOTRETINOIN; PLATINUM DERIVATIVE; TOPOTECAN; VINCRISTINE;

CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CARCINOGENESIS; FAMILIAL CANCER; GENE AMPLIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HISTOLOGY; HUMAN; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; MYELOABLATIVE CONDITIONING; NEUROBLASTOMA; REVIEW; TUMOR DIFFERENTIATION;

BRAIN NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS; RISK FACTORS;

EID: 80053544249     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.103     Document Type: Review

References (109)

1. Ries LAG, Smith MA, Gurney JG et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. National Cancer Institute, SEER Program. NIH, MD, USA, Pub. No. 99-4649 (1999)
2. Navalkele P, ODorisio MS, ODorisio TM, Zamba GKD, Lynch CF. Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr. Blood Cancer 56(1), 50-57 (2011)
3. Moroz V, Machin D, Faldum A et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur. J. Cancer 47(4), 561-571 (2011)
4. Nickerson HJ, Matthay KK, Seeger RC et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Childrens Cancer Group study. J. Clin. Oncol. 18(3), 477-486 (2000) (Pubitemid 30078529)
5. Hero B, Simon T, Spitz R et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J. Clin. Oncol. 26(9), 1504-1510 (2008)
6. Rubie H, De Bernardi B, Gerrard M et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J. Clin. Oncol. 29(4), 449-455 (2011)
7. Perez CA, Matthay KK, Atkinson JB et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a Childrens Cancer Group study. J. Clin. Oncol. 18(1), 18-26 (2000) (Pubitemid 30036332)
8. Baker DL, Schmidt ML, Cohn SL et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N. Engl. J. Med. 363(14), 1313-1323 (2010)
9. Attiyeh EF, London WB, Mosse YP et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353(21), 2243-2253 (2005) (Pubitemid 41697287)
10. Seeger RC, Brodeur GM, Sather H et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 313(18), 1111-1116 (1985) (Pubitemid 16216827)
11. Chen Y, Takita J, Choi YL et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455(7215), 971-974 (2008)
12. George RE, Sanda T, Hanna M et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455(7215), 975-978 (2008)
13. Janoueix-Lerosey I, Lequin D, Brugires L et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455(7215), 967-997 (2008)
14. Mossé YP, Laudenslager M, Longo L et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215), 930-935 (2008)
15. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem. J. 420(3), 345-361 (2009)
16. Mossé Y, Wood A, Maris J. Inhibition of ALK signaling for cancer therapy. Clin. Cancer Res. 15(18), 5609-5614 (2009)
17. Mosse YP, Laudenslager M, Khazi D et al. Germline PHOX2B mutation in hereditary neuroblastoma. Am. J. Hum. Genet. 75(4), 727-730 (2004) (Pubitemid 39244788)
18. Trochet D, OBrien LM, Gozal D et al. PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. Am. J. Hum. Genet. 76(3), 421-426 (2005) (Pubitemid 40250522)
19. Raabe EH, Laudenslager M, Winter C et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene 27(4), 469-476 (2008)
20. Clausen N, Andersson P, Tommerup N. Familial occurrence of neuroblastoma, von Recklinghausens neurofibromatosis, Hirschsprungs agangliosis and jaw-winking syndrome. Acta Paediatr. Scand. 78(5), 736-741 (1989) (Pubitemid 19232309)
21. Rohrer T, Trachsel D, Engelcke G, Hammer J. Congenital central hypoventilation syndrome associated with Hirschsprungs disease and neuroblastoma: case of multiple neurocristopathies. Pediatr. Pulmonol. 33(1), 71-76 (2002) (Pubitemid 34031557)
22. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16(11), 2985-2995 (1997) (Pubitemid 27234938)
23. Hölzel M, Huang S, Koster J et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142(2), 218-229 (2010)
24. Wang K, Diskin SJ, Zhang H et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 469(7329), 216-220 (2010)
25. Capasso M, Devoto M, Hou C et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat. Genet. 41(6), 718-723 (2009)
26. Maris JM, Mosse YP, Bradfield JP et al. Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N. Engl. J. Med. 358(24), 2585-2593 (2008) (Pubitemid 351831359)
27. Diskin SJ, Hou C, Glessner JT et al. Copy number variation at 1q21.1 associated with neuroblastoma. Nature 459(7249), 987-991 (2009)
28. Riley RD, Heney D, Jones DR et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin. Cancer Res. 10(1 Pt 1), 4-12 (2004) (Pubitemid 38114154)
29. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N. Engl. J. Med. 311(4), 231-235 (1984) (Pubitemid 14087665)
30. Bown N, Cotterill S, Lastowska M et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med. 340(25), 1954-1961 (1999) (Pubitemid 29288271)
31. Attiyeh EF, London WB, Mossé YP et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353(21), 2243-2253 (2005) (Pubitemid 41697287)
32. Ambros PF, Ambros IM, Brodeur GM et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br. J. Cancer 100(9), 1471-1482 (2009)
33. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224(4653), 1121-1124 (1984) (Pubitemid 14106392)
34. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 29(9), 1249-1259 (2010)
35. Ohira M, Nakagawara A. Global genomic and RNA profiles for novel risk stratification of neuroblastoma. Cancer Sci, 101(11), 2295-2301 (2010)
36. Berwanger B, Hartmann O, Bergmann E et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2(5), 377-386 (2002) (Pubitemid 41039104)
37. Ohira M, Oba S, Nakamura Y et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 7(4), 337-350 (2005) (Pubitemid 40544651)
38. Schramm A, Schulte JH, Klein-Hitpass L et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 24(53), 7902-7912 (2005) (Pubitemid 41715196)
39. Asgharzadeh S, Pique-Regi R, Sposto R et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J. Natl Cancer Inst. 98(17), 1193-1203 (2006) (Pubitemid 44390990)
40. Oberthuer A, Berthold F, Warnat P et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J. Clin. Oncol. 24(31), 5070-5078 (2006) (Pubitemid 46631411)
41. Lastowska M, Viprey V, Santibanez-Koref M et al. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 26(53), 7432-7444 (2007) (Pubitemid 350158715)
42. Tomioka N, Oba S, Ohira M et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 27(4), 441-449 (2008)
43. Oberthuer A, Hero B, Berthold F et al. Prognostic impact of gene expression-based classification for neuroblastoma. J. Clin. Oncol. 28(21), 3506-3515 (2010)
44. Westermann F, Muth D, Benner A et al. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 9(10), R150 (2008)
45. Chen QR, Song YK, Wei JS et al. An integrated cross-platform prognosis study on neuroblastoma patients. Genomics 92(4), 195-203 (2008)
46. Vermeulen J, De Preter K, Naranjo A et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 10(7), 663-671 (2009)
47. De Preter K, Vermeulen J, Brors B et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin. Cancer Res. 16(5), 1532-1541 (2010)
48. Schulte JH, Schowe B, Mestdagh P et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int. J. Cancer 127(10), 2374-2385 (2010)
49. Bilke S, Chen QR, Westerman F, Schwab M, Catchpoole D, Khan J. Inferring a tumor progression model for neuroblastoma from genomic data. J. Clin. Oncol. 23(29), 7322-7331 (2005) (Pubitemid 46202345)
50. Selzer RR, Richmond TA, Pofahl NJ et al. Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 44(3), 305-319 (2005) (Pubitemid 41397100)
51. Spitz R, Hero B, Simon T, Berthold F. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma. Clin. Cancer Res. 12(11 Pt 1), 3368-3373 (2006)
52. Stallings RL, Nair P, Maris JM et al. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res. 66(7), 3673-3680 (2006)
53. Michels E, Vandesompele J, De Preter K et al. Array CGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 46(12), 1098-1108 (2007) (Pubitemid 47614544)
54. Schleiermacher G, Michon J, Huon I et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br. J. Cancer 97(2), 238-246 (2007) (Pubitemid 47057465)
55. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A et al. Accumulation of segmental alterations determines progression in neuroblastoma. J. Clin. Oncol. 28(19), 3122-3130 (2010)
56. Cohn SL, Pearson ADJ, London WB et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol. 27(2), 289-297 (2009)
57. Shimada H, Ambros IM, Dehner LP et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86(2), 364-372 (1999) (Pubitemid 29327594)
58. Monclair T, Brodeur GM, Ambros PF et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J. Clin. Oncol. 27(2), 298-303 (2009)
59. Matthay KK, Shulkin B, Ladenstein R et al. Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br. J. Cancer 102(9), 1319-1326 (2010)
60. Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F. Review of image defined risk factors in localized neuroblastoma patients: results of the GPOH NB97 trial. Pediatr. Blood Cancer 50(5), 965-969 (2008) (Pubitemid 351500172)
61. London WB, Frantz CN, Campbell LA et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Childrens Oncology Group study. J. Clin. Oncol. 28(24), 3808-3815 (2010)
62. Kushner BH, LaQuaglia MP, Bonilla MA et al. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J. Clin. Oncol. 12(12), 2607-2613 (1994) (Pubitemid 24379646)
63. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J. Clin. Oncol. 9(6), 1050-1058 (1991)
64. Beiske K, Burchill SA, Cheung IY et al. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Br. J. Cancer 100(10), 1627-1637 (2009)
65. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr. Blood Cancer 44(4), 348-357 (2005) (Pubitemid 40316027)
66. Matthay KK, Villablanca JG, Seeger RC et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Childrens Cancer Group. N. Engl. J. Med. 341(16), 1165-1173 (1999) (Pubitemid 29480654)
67. Berthold F, Boos J, Burdach S et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 6(9), 649-658 (2005) (Pubitemid 41222755)
68. Matthay KK, Reynolds CP, Seeger RC et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a childrens oncology group study. J. Clin. Oncol. 27(7), 1007-1013 (2009)
69. George RE, Li S, Medeiros-Nancarrow C et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J. Clin. Oncol. 24(18), 2891-2896 (2006) (Pubitemid 46630591)
70. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Childrens Oncology Group (CCG 09709). J. Clin. Oncol. 24(21), 3423-3430 (2006) (Pubitemid 46638899)
71. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J. Natl Cancer Inst. 91(13), 1138-1146 (1999) (Pubitemid 29330552)
72. Garaventa A, Luksch R, Lo Piccolo MS et al. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin. Cancer Res. 9(6), 2032-2039 (2003) (Pubitemid 36687622)
73. Yu AL, Gilman AL, Ozkaynak MF et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363(14), 1324-1334 (2010)
74. Treuner J, Feine U, Niethammer D et al. Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet 1(8372), 333-334 (1984)
75. Haas-Kogan DA, Swift PS, Selch M et al. Impact of radiotherapy for high-risk neuroblastoma: a Childrens Cancer Group study. Int. J. Radiat. Oncol. Biol. Phys. 56(1), 28-39 (2003) (Pubitemid 36403674)
76. DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl. Med. Biol. 35(Suppl. 1), S35-S48 (2008)
77. Matthay KK, Tan JC, Villablanca JG et al. Phase I dose escalation of iodine-131- metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J. Clin. Oncol. 24(3), 500-506 (2006) (Pubitemid 46630470)
78. Lu L, Ghose AK, Quail MR et al. ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. Biochemistry 48(16), 3600-3609 (2009)
79. Otto T, Horn S, Brockmann M et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15(1), 67-78 (2009)
80. Maris JM, Morton CL, Gorlick R et al. Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr. Blood Cancer 55(1), 26-34 (2010)
81. De Brouwer S, De Preter K, Kumps C et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin. Cancer Res. 16(17), 4353-4362 (2010)
82. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin. Cancer Res. 6(5), 1900-1908 (2000) (Pubitemid 30305088)
83. Sims TL, Williams RF, Ng CY, Rosati SF, Spence Y, Davidoff AM. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery 144(2), 269-275 (2008) (Pubitemid 352010323)
84. Keshelava N, Davicioni E, Wan Z et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J. Natl Cancer Inst. 99(14), 1107-1119 (2007) (Pubitemid 47241395)
85. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM. Modulation of radiation response by histone deacetylase inhibition. Int. J. Radiat. Oncol. Biol. Phys. 62(1), 223-229 (2005) (Pubitemid 40591946)
86. Fouladi M, Park JR, Stewart CF et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Childrens Oncology Group phase I consortium report. J. Clin. Oncol. 28(22), 3623-3629 (2010)
87. Jubert C, Wall DA, Grimley M, Champagne MA, Duval M. Engraftment of unrelated cord blood after reduced-intensity conditioning regimen in children with refractory neuroblastoma: a feasibility trial. Bone Marrow Transplant. 46(2), 232-237 (2010)
88. Huebener N, Fest S, Strandsby A et al. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Mol. Cancer Ther. 7(7), 2241-2251 (2008)
89. Fest S, Huebener N, Weixler S et al. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res. 66(21), 10567-10575 (2006) (Pubitemid 44799780)
90. Croce M, Meazza R, Orengo AM et al. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol. Immunother. 57(11), 1625-1634 (2008)
91. Fest S, Huebener N, Bleeke M et al. Survivin minigene DNA vaccination is effective against neuroblastoma. Int. J. Cancer 125(1), 104-114 (2009)
92. Zhang L, Smith KM, Chong AL et al. In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia 11(5), 426-435 (2009)
93. Maris JM, Courtright J, Houghton PJ et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr. Blood Cancer 51(1), 42-48 (2008) (Pubitemid 351717388)
94. Nilsson MB, Zage PE, Zeng L et al. Multiple receptor tyrosine kinases regulate HIF-1a and HIF-2a in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 29(20), 2938-2949 (2010)
95. Donfrancesco A, De Ioris MA, McDowell HP et al. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response. Pediatr. Blood Cancer 54(1), 55-61 (2010)
96. Iyer R, Evans AE, Qi X et al. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin. Cancer Res. 16(5), 1478-1485 (2010)
97. Houghton PJ, Morton CL, Gorlick R et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 54(7), 921-926 (2010)
98. Bender A, Opel D, Naumann I et al. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene 30(4), 494-503 (2010)
99. Chesler L, Schlieve C, Goldenberg DD et al. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 66(16), 8139-8146 (2006) (Pubitemid 44299181)
100. Li Z, Tan F, Liewehr DJ, Steinberg SM, Thiele CJ. In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine. J. Natl Cancer Inst. 102(11), 758-770 (2010)
101. Feldman ME, Shokat KM. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor kinase domain inhibitors (TORKinibs). Curr. Top. Microbiol. Immunol. 347, 241-262 (2010)
102. Witt O, Deubzer HE, Lodrini M, Milde T, Oehme I. Targeting histone deacetylases in neuroblastoma. Curr. Pharm. Des. 15(4), 436-447 (2009)
103. Kim E, Shohet J. Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis. J. Natl Cancer Inst. 101(22), 1527-1529 (2009)
104. Yu AL, Gilman AL, Ozkaynak MF et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363(14), 1324-1334 (2010)
105. National Cancer Institute www.target.cancer.gov
106. Pediatric Preclinical Testing Program www.pptp.nchresearch.org
107. NANT www.nant.org
108. A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (2010). www.clinicaltrials.gov/ ct2/show/NCT0118 2896?term=NCT01182896&rank=1.
109. PF-02341066 in Treating Young Patients with Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma (2010) www.clinicaltrials.gov/ct2/show/ NCT009 39770?term=NCT00939770&rank=1